
Nyxoah SA (NYXH) Stock Forecast & Price Target
Nyxoah SA (NYXH) Analyst Ratings
Bulls say
Nyxoah is positioned for strong future growth with its successful U.S. commercial launch, as indicated by the positive leading indicators for new account adds and patient funnel development. Management's disciplined cost control and upcoming results from the ACCCESS study are additional catalysts for potential expansion and increased market share throughout 2026 and 2027. Despite potential risks such as competition from market leader Inspire Medical Systems and the need for additional capital, the overall outlook for Nyxoah is positive.
Bears say
Nyxoah is a highly innovative and promising company within the sleep-disordered breathing market, with its lead solution, the Genio system, showing potential for treating moderate to severe OSA. However, despite the company's recent upward guidance for FY26 revenue, there are concerns about its projected profitability, as management has guided for lower gross margins and higher operating expenses. Also, the company's decline in valuation multiple in the medtech sector raises questions about its long-term growth potential.
This aggregate rating is based on analysts' research of Nyxoah SA and is not a guaranteed prediction by Public.com or investment advice.
Nyxoah SA (NYXH) Analyst Forecast & Price Prediction
Start investing in Nyxoah SA (NYXH)
Order type
Buy in
Order amount
Est. shares
0 shares